A cross-sectional study conducted on 543 Multiple Sclerosis patients suggested that most Multiple Sclerosis patients developed a mild course of COVID-19 infection. The study was conducted to identify suspected COVID-19 cases and associated factors in Multiple Sclerosis patients by interrogation over phone and evaluating the medical records. Common symptoms suspicious for COVID-19 infection included dyspnea, sore throat, anosmia or dysgeusiain, cough, GI symptoms and fever. Patients on treatment with interferon beta & glatiramer acetate developed mild COVID-19 infection without severe complications. Treatment with anti-CD20 antibody inhibitors such as rituximab led to the development of severe COVID-19 disease resulting in death.
